{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous+Sclerosis&page=2",
    "query": {
      "condition": "Cutaneous Sclerosis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous+Sclerosis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T18:33:39.489Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04680975",
      "title": "Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Belumosudil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kadmon, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2021-03-03",
      "completion_date": "2022-12-19",
      "has_results": true,
      "last_update_posted_date": "2023-06-05",
      "last_synced_at": "2026-06-26T18:33:39.489Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04680975"
    },
    {
      "nct_id": "NCT01031901",
      "title": "Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberous Sclerosis",
        "Neurofibromatoses",
        "Angiofibroma",
        "Neurofibroma"
      ],
      "interventions": [
        {
          "name": "Skincerity",
          "type": "DRUG"
        },
        {
          "name": "Skincerity plus sirolimus/rapamycin",
          "type": "DRUG"
        },
        {
          "name": "Skinercity plus sirolimus/rapamycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2009-12",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2012-02-27",
      "last_synced_at": "2026-06-26T18:33:39.489Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01031901"
    },
    {
      "nct_id": "NCT02166229",
      "title": "Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Scleroderma",
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Divalproex sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-06",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2016-08-11",
      "last_synced_at": "2026-06-26T18:33:39.489Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02166229"
    },
    {
      "nct_id": "NCT02465437",
      "title": "Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "JBT-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Part B Open-Label Extension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corbus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 42,
      "start_date": "2015-08",
      "completion_date": "2020-12-11",
      "has_results": true,
      "last_update_posted_date": "2021-04-21",
      "last_synced_at": "2026-06-26T18:33:39.489Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465437"
    },
    {
      "nct_id": "NCT04138485",
      "title": "Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "IgPro10",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-12-20",
      "completion_date": "2020-09-16",
      "has_results": false,
      "last_update_posted_date": "2020-11-17",
      "last_synced_at": "2026-06-26T18:33:39.489Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04138485"
    },
    {
      "nct_id": "NCT02283762",
      "title": "Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scleroderma, Systemic"
      ],
      "interventions": [
        {
          "name": "Riociguat (Adempas, BAY63-2521)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2015-01-15",
      "completion_date": "2019-03-28",
      "has_results": true,
      "last_update_posted_date": "2020-02-05",
      "last_synced_at": "2026-06-26T18:33:39.489Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02283762"
    },
    {
      "nct_id": "NCT05626751",
      "title": "An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis",
        "Sclerosis, Systemic"
      ],
      "interventions": [
        {
          "name": "HZN-825",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 174,
      "start_date": "2022-11-04",
      "completion_date": "2025-02-24",
      "has_results": true,
      "last_update_posted_date": "2026-01-05",
      "last_synced_at": "2026-06-26T18:33:39.489Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05626751"
    },
    {
      "nct_id": "NCT06708845",
      "title": "US Zamto-cel Autoimmune Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lupus Nephritis",
        "Systemic Lupus Erythematosus",
        "Systemic Sclerosis (SSc)",
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "zamtocabtagene autoleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Miltenyi Biomedicine GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2026-07",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-06-26T18:33:39.489Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06708845"
    },
    {
      "nct_id": "NCT04478994",
      "title": "A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "TEPEZZA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 3,
      "start_date": "2021-11-17",
      "completion_date": "2022-12-08",
      "has_results": true,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-06-26T18:33:39.489Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04478994"
    },
    {
      "nct_id": "NCT06400303",
      "title": "KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Systemic Sclerosis - Diffuse Cutaneous",
        "Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria"
      ],
      "interventions": [
        {
          "name": "KYV-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard lymphodepletion regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kyverna Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2024-08-06",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-06-26T18:33:39.489Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Great Neck, New York",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06400303"
    }
  ]
}